EUCTR2005-005219-36-IT进行中（未招募）不适用
A Phase 2 Single-Arm study of gemcitabine in combination with Oxaliplatin in Pediatric patients with relapsed or refractory neuroblastoma or miscellaneous solid non-CNS tumors - ND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ELI LILLY
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1 Histologically proven malignancy at diagnosis either neuroblastoma or other non-CNS solid tumors excluding osteosarcoma . 2 Measurable primary and/or metastatic disease 3 Relapsed or refractory tumors in which standard approaches to treatment have failed. 4 No more than one salvage therapy for relapsed or refractory disease. 5 6 months to 18 years of age. 6 Lansky play score 70 , or Eastern Cooperative Oncology Group ECOG performance status 1 where more appropriate . 7 Life expectancy 3 months. 8 Adequate organ function
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1 Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. 2 Concurrent administration of any other antitumor therapy. 3 Have a serious concomitant systemic disorder for example, active infection including HIV, or cardiac disease that, in the opinion of the investigator, would compromise the patient s ability to complete the study. 4 Have symptomatic brain metastases. 5 Pre-existing sensory or motor neuropathy Grade 2 excluding neuropathy due to disease .
研究者
相似试验
进行中（未招募）
1 期
Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory and relapsed pediatric solid tumors. - ITCC-004-GEMOXRefractory or relapsing malignant pediatric solid tumors.EUCTR2006-001065-41-GBniversity Hospitals of Leicester NHS Trust, Research and Development Directorate156
进行中（未招募）
不适用
Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory and relapsed pediatric solid tumors - ITCC-004-GEMOXrefractory or relapsing malignant pediatric solid tumorsEUCTR2006-001065-41-DEInstitut Gustave Roussy156
进行中（未招募）
不适用
Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory and relapsed pediatric solid tumors.(Etude de phase II de l’association Gemcitabine - Oxaliplatine « GEMOX » chez les patients porteurs d’une tumeur solide maligne réfractaire ou en rechute). - ITCC-004-GEMOXrefractory or relapsing malignant pediatric solid tumors.EUCTR2006-001065-41-NLInstitut Gustave Roussy156
进行中（未招募）
1 期
A Phase 2 Single-Arm Study of Gemcitabine in Combination with Oxaliplatin in Pediatric Patients with Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors - N/AEUCTR2005-005219-36-GBEli Lilly and Company Limited70
进行中（未招募）
不适用
A Phase 2 Single-Arm Study of Gemcitabine in Combination with Oxaliplatin in Pediatric Patients with Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS TumorsEUCTR2005-005219-36-DEEli Lilly and Company Limited70